Real-world evidence on first- and second-line palliative chemotherapy in advanced pancreatic cancer
Hakon Blomstrand, Atul Batra, Winson Y. Cheung, Nils Elander
Abstract
gemcitabine plus nab-paclitaxel (GnP) and folfirinox (FFX), is similar in RCTs and real-life populations. Outcomes of second-line therapy following failure of first-line regimens are still dismal, and considerable uncertainty of the optimal management remains. Additional RCTs and real-world evidence studies focusing on the optimal treatment sequence, such as FFX followed by GnP or vice versa, are urgently needed. Finally, the review highlights the need for prognostic and predictive biomarkers to inform clinical decision making and enable personalized management in advanced PDAC.
Topics & Concepts
MedicineClinical OncologyPancreatic cancerOncologyInternal medicineCancerBreast cancerChemotherapyPancreatic and Hepatic Oncology ResearchRenal cell carcinoma treatmentCancer Genomics and Diagnostics